S&P 500 7,412.61 -1.15% NASDAQ 25,127.98 -2.19% DOW 51,715.59 -0.96% R2K 2,940.80 -0.65% VIX 19.06 +14.54% US 10Y 4.70 +1.03% DXY 101.47 +0.33% GOLD 4,056.40 -2.18% CRUDE 91.84 +5.77% BITCOIN 64,975.34 -1.70%

S&P 500 7,412.61 -1.15% NASDAQ 25,127.98 -2.19% DOW 51,715.59 -0.96% R2K 2,940.80 -0.65% VIX 19.06 +14.54% US 10Y 4.70 +1.03% DXY 101.47 +0.33% GOLD 4,056.40 -2.18% CRUDE 91.84 +5.77% BITCOIN 64,975.34 -1.70%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

AVXL

Anavex Life Sciences Corp. NMS · AVXL

$2.52 -0.03 (-1.37%)

Neutral · -0.17σ

+ Compare Open in Sniper

News · AVXL

Full news feed →

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. · 210d ago

Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug

Investing.com · 251d ago

Alzheimer's Disease Disease-Modifying Therapies Markets, 2023-2025 & 2026-2030 | Key Marketed Products, Clinical Trials, Competitive Scenario and R&D Activities

GlobeNewswire Inc. · 352d ago

ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm

GlobeNewswire Inc. · 401d ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

GlobeNewswire Inc. · 473d ago

Anavex Life Sciences: Short-Squeeze Target Gains Traction

Investing.com · 572d ago

US Stocks To Open Higher As Wall Street Expects 'Santa Rally' In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus

Benzinga · 577d ago

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?

Benzinga · 621d ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire Inc. · 686d ago

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

GlobeNewswire Inc. · 724d ago

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire Inc. · 763d ago

Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire Inc. · 792d ago

Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 798d ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

GlobeNewswire Inc. · 800d ago

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

GlobeNewswire Inc. · 805d ago

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

GlobeNewswire Inc. · 833d ago

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

GlobeNewswire Inc. · 857d ago

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

GlobeNewswire Inc. · 878d ago

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Zacks Investment Research · 901d ago

Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal

Zacks Investment Research · 903d ago

GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance

Zacks Investment Research · 903d ago

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade

Zacks Investment Research · 903d ago

New Strong Buy Stocks for January 31st

Zacks Investment Research · 904d ago